VANCOUVER, British Columbia, Nov. 01, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has established the optimum peak stimulation period of 6 hours for neuron outgrowth by AP-188 (“N,N-Dimethyltryptamine” or “DMT”) in its pre-clinical…


Previous articlePsychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures Ethics Approval; UCL Joins the Renaissance
Next articleatai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia